Comprehensive evaluation of a novel nuclear factor-kappaB inhibitor, quinoclamine, by transcriptomic analysis
W-Y Cheng1, J-C Lien, C-Y Hsiang
1Molecular Biology Laboratory, Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan.
Background And Purpose:
The transcription factor nuclear factor-kappaB (NF-kappaB) has been linked to the cell growth, apoptosis and cell cycle progression. NF-kappaB blockade induces apoptosis of cancer cells. Therefore, NF-kappaB is suggested as a potential therapeutic target for cancer. Here, we have evaluated the anti-cancer potential of a novel NF-kappaB inhibitor, quinoclamine (2-amino-3-chloro-1,4-naphthoquinone).
Experimental Approach:
In a large-scale screening test, we found that quinoclamine was a novel NF-kappaB inhibitor. The global transcriptional profiling of quinoclamine in HepG2 cells was therefore analysed by transcriptomic tools in this study.
Key Results:
Quinoclamine suppressed endogenous NF-kappaB activity in HepG2 cells through the inhibition of IkappaB-alpha phosphorylation and p65 translocation. Quinoclamine also inhibited induced NF-kappaB activities in lung and breast cancer cell lines. Quinoclamine-regulated genes interacted with NF-kappaB or its downstream genes by network analysis. Quinoclamine affected the expression levels of genes involved in cell cycle or apoptosis, suggesting that quinoclamine exhibited anti-cancer potential. Furthermore, quinoclamine down-regulated the expressions of UDP glucuronosyltransferase genes involved in phase II drug metabolism, suggesting that quinoclamine might interfere with drug metabolism by slowing down the excretion of drugs.
Conclusion And Implications:
This study provides a comprehensive evaluation of quinoclamine by transcriptomic analysis. Our findings suggest that quinoclamine is a novel NF-kappaB inhibitor with anti-cancer potential.
Insights
Quinoclamine, a novel inhibitor of nuclear factor-kappaB (NF-kappaB), demonstrates anti-cancer potential by suppressing cancer cell growth and inducing apoptosis. This study highlights its therapeutic promise for cancer treatment.
Area of Science:
- Molecular Biology
- Cancer Research
- Pharmacology
Background:
- Nuclear factor-kappaB (NF-kappaB) is a key regulator of cell growth, apoptosis, and cell cycle progression.
- Inhibition of NF-kappaB activity has shown promise in inducing apoptosis in cancer cells, positioning it as a therapeutic target.
- Quinoclamine, a novel compound, was identified as a potential NF-kappaB inhibitor.
Purpose of the Study:
- To evaluate the anti-cancer potential of quinoclamine, a novel NF-kappaB inhibitor.
- To investigate the molecular mechanisms underlying quinoclamine's effects using transcriptomic analysis.
- To assess quinoclamine's impact on NF-kappaB activity and downstream gene expression in cancer cells.
Main Methods:
- Large-scale screening to identify quinoclamine as an NF-kappaB inhibitor.
- Transcriptomic analysis of quinoclamine in HepG2 cells to understand global gene expression changes.
- Analysis of NF-kappaB activity, including IkappaB-alpha phosphorylation and p65 translocation.
- Network analysis to identify interactions between quinoclamine-regulated genes and NF-kappaB pathways.
- Evaluation of quinoclamine's effect on genes involved in cell cycle and apoptosis.
Main Results:
- Quinoclamine suppressed endogenous NF-kappaB activity in HepG2 cells by inhibiting IkappaB-alpha phosphorylation and p65 translocation.
- Quinoclamine demonstrated inhibitory effects on induced NF-kappaB activities in lung and breast cancer cell lines.
- Network analysis revealed that quinoclamine-regulated genes are linked to NF-kappaB and its downstream targets.
- Quinoclamine modulated the expression of genes associated with cell cycle regulation and apoptosis.
- Quinoclamine downregulated UDP glucuronosyltransferase genes, suggesting potential interference with phase II drug metabolism.
Conclusions:
- Quinoclamine is a novel NF-kappaB inhibitor with demonstrated anti-cancer potential.
- Transcriptomic analysis provides a comprehensive understanding of quinoclamine's molecular effects.
- Quinoclamine's ability to modulate cell cycle and apoptosis pathways supports its therapeutic promise.
- Potential interference with drug metabolism warrants further investigation.
